iiinova — where your digital self keeps evolving

Boulton Lab @boultonlab.bsky.social · 09/01/2026

We are excited to share that our latest work from the lab aimed at understanding how the tRNA nuclease SLFN11 is activated in response to DNA damage and replication stress has just been published in @natcellbio.nature.com! Open access link: www.nature.com/articles/s41... (1/9)

nature.com

Client Challenge

13612

Reposted by Boulton Lab

The West Lab @ The Crick @westlabcrick.bsky.social · 07/11/2025

‼️ Excited to share our new paper out now in @science.org ‼️ We describe a new tetrameric RAD51 paralog complex – XRCC3-RAD51C-RAD51D-XRCC2 – which caps the end of RAD51 filaments. Link: www.science.org/doi/epdf/10.... Thread ⬇️ (1/8)

17919

Boulton Lab @boultonlab.bsky.social · 11/09/2025

New preprint from the lab led by @ssegurabayona.bsky.social identifying SLFN11 activity as a barrier to ALT establishment.

040

Reposted by Boulton Lab

Sandra Segura-Bayona @ssegurabayona.bsky.social · 11/09/2025

🚀 New preprint alert! We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis. 📄 Read the manuscript here: www.biorxiv.org/content/10.1...

biorxiv.org

SLFN11 restricts escape from telomere crisis to prevent alternative lengthening of telomeres

The tRNA nuclease SLFN11 is epigenetically silenced in ~50% of treatment-naive tumours and is the strongest predictor of chemoresistance but why it is frequently inactivated in cancer is unknown. To a...

12210

Reposted by Boulton Lab

Román González-Prieto @romangp.bsky.social · 30/05/2025

Save de date! Join us at @cabimer.bsky.social on October 17th for the @GenomaHubCSIC Workshop in "Genome Dynamics in Development and Disease". Slots available for talks! Registration opens soon!!

078

Boulton Lab @boultonlab.bsky.social · 27/05/2025

We are looking to recruit three posts at the @crick.ac.uk in structural biology, cell biology, and pharmacology to join a 20+ strong multidisciplinary team focused on delivering the first precision medicines for the treatment of ALT cancers. Interested? Please check out the advertised jobs below:

134

Reposted by Boulton Lab

The Francis Crick Institute @crick.ac.uk · 21/05/2025

Read our Q&A with Simon Boulton (@boultonlab.bsky.social), a group leader here at the Crick who co-founded the company Artios in 2016. Artios is a biotech company that develops cancer treatments that target DNA damage response pathways. www.crick.ac.uk/news-and-fea...

crick.ac.uk

From the lab to the clinic: developing the next generation of precision cancer therapies

Crick group leader Simon Boulton co-founded Artios in 2016, a spin-out from Cancer Research UK’s Commercial Partnerships, where he is now VP of Science Strategy. Artios develops cancer treatments that...

096

Reposted by Boulton Lab

Ryan Cross @scienceboss.bsky.social · 29/04/2025

Artios Pharma presented data on its ATR inhibitor (blocks a key DNA damage response enzyme) at #AACR25 today. 50% response (tumor shrinkage) in patients whose tumors lacked a counterpart DNA repair enzyme called ATM. Read more in my story for @endpts.com endpts.com/artios-cance...

endpts.com

Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study

Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a subset of patients with advanced cancer.

072